4 assets in Bilateral Breast Carcinoma

Therapeutic assets addressing Bilateral Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Bilateral Breast Carcinoma	Academic and Community Cancer Research United	P2	CCC (53)
Ixabepilone Bilateral Breast Carcinoma	M.D. Anderson Cancer Center	P2	CCC (53)
Sargramostim Bilateral Breast Carcinoma	Academic and Community Cancer Research United	P2	CCC (53)
Berzosertib Bilateral Breast Carcinoma	National Cancer Institute (NCI)	P1	CC (43)